Reni, Michele
Balzano, Gianpaolo
Zanon, Silvia
Passoni, Paolo
Nicoletti, Roberto
Arcidiacono, Paolo Giorgio
Pepe, Gino
Doglioni, Claudio
Fugazza, Clara
Ceraulo, Domenica
Falconi, Massimo
Gianni, Luca
Article History
Received: 22 February 2016
Revised: 23 April 2016
Accepted: 13 June 2016
First Online: 12 July 2016
Competing interests
: This work was supported by Celgene, which provided funding for the study with an unrestricted grant and the supply of the drug. MR discloses: advisory role for Celgene, Boehringer Ingelheim, Genetech, Lilly, Merck Serono, Baxalta; research funding to his institution from Celgene, PharmaMar, and Novartis; expenses reimbursement from Celgene. GB discloses: advisory role for Celgene. MF discloses: research funding to his institution from Novartis. LG discloses: consulting or advisory role for Roche, Pfizer, GlaxoSmithKline, Synthon, Taiho Pharmaceutical, AstraZeneca, Genomic Health, Merck Sharp & Dohme, Boehringer Ingelheim, Tiziana Pharma, Synaffix, and Celgene; patents/royalties/other intellectual property with Roche. All other authors disclose no conflict of interest.